StreetInsider

• Log in to your account:

  
  Log in
• Signup
• Home
• EPS Insider
• Event Calendar
• Conferences
• Classic Site

Upgrade to SI Premium - Free Trial

Aktis Oncology (AKTS)

Leerink Assumes Aktis Oncology (AKTS) at Outperform July 21, 2026 4:49 PM - StreetInsider Aktis Oncology (AKTS) PT Raised to $33 at JPMorgan July 14, 2026 7:42 AM - StreetInsider Raymond James Starts Aktis Oncology (AKTS) at Strong Buy (correction) June 15, 2026 4:08 PM - StreetInsider Akoustis Technologies (AKTS) PT Raised to $35 at H.C. Wainwright June 3, 2026 6:49 AM - StreetInsider Aktis Oncology to Present at the Jefferies Global Healthcare Conference May 27, 2026 4:05 PM - StreetInsider Aktis reports imaging data for cancer drug targeting B7-H3 protein May 21, 2026 5:36 PM - StreetInsider Aktis Oncology Reports First-in-Human Clinical Imaging and Dosimetry Data for AKY-2519 Demonstrating Robust Tumor Uptake and Limited Normal Tissue Exposures in Patients with B7-H3 Expressing Tumors May 21, 2026 5:21 PM - Globe NewsWire Aktis Oncology Reports Financial Results and Business Highlights for First Quarter 2026 May 11, 2026 4:01 PM - StreetInsider Aktis Oncology to Present at the BofA Securities Health Care Conference May 6, 2026 8:00 AM - Globe NewsWire Aktis Oncology starts Phase 1b trial for prostate cancer drug AKY-2519 May 4, 2026 4:05 PM - StreetInsider Aktis Oncology Initiates Phase 1b Clinical Trial for AKY-2519, a B7-H3 Miniprotein Radioconjugate, in Metastatic Castration-Resistant Prostate Cancer (mCRPC) May 4, 2026 4:05 PM - Globe NewsWire Two River and Vida Ventures Extend Track Record of Company Creation and Value Realization Following the Candid Therapeutics’ Acquisition by UCB May 3, 2026 8:00 PM - BizWire William Blair Starts Akoustis Technologies (AKTS) at Outperform April 29, 2026 6:40 AM - StreetInsider Full Article List